Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4528867 | 0.91 | KDM4E (0.47) | KDM4ETRPM8TP53NPC1MAPT | |
| SCHEMBL4533878 | 0.90 | KDM4E (0.48) | KDM4ETRPM8TP53NPC1MAPT | |
| SCHEMBL4523204 | 0.89 | KDM4E (0.49) | KDM4ENPSR1 | |
| SCHEMBL8239980 | 0.85 | IKBKB (0.43) | KDM4EALDH1A1 | |
| SCHEMBL27724629 | 0.81 | TP53 (0.55) | KDM4ETP53MAPTSMN1; SMN2HPGD | |
| SCHEMBL4518456 | 0.80 | MAPT (0.43) | KDM4EMAPTALDH1A1 | |
| SCHEMBL4524608 | 0.79 | KAT2B (0.42) | KDM4ETP53MAPTLMNAPOLB | |
| SCHEMBL13605661 | 0.79 | TP53 (0.45) | KDM4ETP53MAPTCYP1A2CYP2C9 | |
| SCHEMBL8231106 | 0.79 | TP53 (0.48) | TP53MAPTLMNAPOLBALDH1A1 | |
| SCHEMBL4533208 | 0.78 | KDM4E (0.49) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326001-A1 | THIENOPYRIDINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | RICHTER GEDEON NYRT. (HU) | 2009-12-31 | — | — | US | claimed |
| EP-1971609-A1 | THIENOPYRIDINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Richter Gedeon NYRT (HU) | 2008-09-24 | — | — | EP | claimed |
| WO-2007072090-A1 | THIENOPYRIDINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | RICHTER GEDEON NYRT. (HU) | 2007-06-28 | — | — | WO | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| US-20090326001-A1 | THIENOPYRIDINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | RICHTER GEDEON NYRT. (HU) | 2009-12-31 | — | — | US | disclosed |
| US-20090326001-A1 | THIENOPYRIDINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | RICHTER GEDEON NYRT. (HU) | 2009-12-31 | — | — | US | disclosed |
| US-20090326001-A1 | THIENOPYRIDINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | RICHTER GEDEON NYRT. (HU) | 2009-12-31 | — | — | US | disclosed |
| WO-2007072090-A1 | THIENOPYRIDINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | RICHTER GEDEON NYRT. (HU) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326001-A1 | THIENOPYRIDINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRIK5 | KDM4E 3491/4885TRPM8 242/4885TP53 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.